Barclays analyst Geoff Meacham remains bullish on shares of Neurocrine Biosciences after hosting meetings in Europe with management. The tone was positive on the commercial dynamic for Ingrezza in tardive dyskinesia as well as the opportunity in Tourette syndrome and for elagolix, Meacham tells investors in a research note. Further, he spent a lot of time discussing opicapone for Parkinson's disease, which he says is an asset for which little value is ascribed. Neurocrine could file a new drug application in the first half of 2019, which is commercially leverageable with its current sales force, Meacham contends. He keeps an Overweight rating on Neurocrine with a $100 price target.